论文部分内容阅读
为了解含何首乌制剂的剂型分布、提取工艺以及何首乌的毒性,对2015版《中国药典》收载的61个含何首乌中成药制剂进行统计分析,并参照国内外文献整理何首乌的毒性反应报道。药典收载的61个含何首乌提取工艺的中成药中,采用水提法的占52.5%,采用醇提法的占20%。文献报道何首乌中可能存在对肝细胞有直接毒性或在肝脏中可转化为有毒的化学成分,所以临床上运用何首乌受到了一定限制。何首乌经过规范合理炮制,其毒性明显降低,因此,应当多方面、多层次加大对何首乌配伍及炮制方法的研究,有效消除其安全隐患。
In order to understand the formulation distribution, extraction process and the toxicity of Polygonum multiflorum Thunb., A total of 61 Polygonum multiflorum proprietary Chinese medicines contained in the 2015 edition of “Chinese Pharmacopoeia” were statistically analyzed and the toxicity responses of Polygonum multiflorum were summarized according to the domestic and foreign literature. Pharmacopoeia 61 containing proprietary Chinese medicines Polygonum multiflorum extraction process, the use of water accounted for 52.5%, with alcohol accounted for 20%. Polygonum multiflorum there may be direct toxicity to liver cells or liver can be transformed into toxic chemical composition, so the clinical use of Polygonum multiflorum has been subject to certain restrictions. Polygonum multiflorum through reasonable and reasonable processing, the toxicity was significantly reduced, therefore, should be multi-faceted, multi-level increase the Polygonum multiflorum compatibility and processing methods to effectively eliminate their potential safety problems.